Firm at a glance
GV is a platform private equity firm founded in 2009 and headquartered in the San Francisco Bay Area, per its own website [S1]. The firm reports approximately $13 billion in assets under management and maintains offices in New York, Cambridge, and London [S1].
What they buy
Based on publicly disclosed portfolio holdings, GV appears to concentrate on technology-enabled businesses across artificial intelligence applications, infrastructure, healthcare AI, and developer tools [S2]. The firm’s observed portfolio pattern includes both early-stage technology companies and more mature platforms spanning enterprise software, consumer technology, life sciences, and frontier technology sectors [S1][S2]. Notable historical investments include Uber, Slack, Stripe, and GitLab, alongside more recent AI-focused companies such as Harvey, Hebbia, and Synthesia [S1][S2].
Portfolio
AI Applications
Vercel, Synthesia, Tessl, Harvey, and Hebbia [S2].
Healthcare AI
insitro and Isomorphic Labs [S2].
Infrastructure
Snorkel, Deepset, SambaNova, Modular, and Lightmatter [S2].
Dev Tools & Security
StackBlitz, GitLab, and Duo Security [S1][S2].
Consumer & Enterprise
Uber, Nest, Slack, Lemonade, Stripe, Wonder, StockX, and Nothing [S1].
Life Sciences
Flatiron Health, Metsera, Verve Therapeutics, One Medical, and Q [S1].
Recent activity (last 24 months)
* Maze Therapeutics (exit, 2025) [S1]
* Metsera (exit, 2025) [S1]
* Caraway Health (exit, 2025) [S1]
* Quartet Health (exit, 2025) [S1]
* Context AI (exit, 2025) [S1]
* Cognosys (exit, 2025) [S1]
* Moonhub (exit, 2025) [S1]
* Veza (exit, 2025) [S1]
* Invetx (exit, 2024) [S1]
* Celsius Therapeutics (exit, 2024) [S1]
* Cacheflow (exit, 2024) [S1]
* PayRange (exit, 2024) [S1]
How this firm fits a seller
GV’s portfolio composition suggests the firm targets technology companies with significant growth trajectories rather than traditional owner-operated businesses. The firm’s recent exit activity, with twelve reported transactions in 2024 and 2025, indicates an active portfolio management approach [S1]. Sellers in artificial intelligence, healthcare technology, or enterprise software sectors may find alignment with GV’s observed investment focus, though the firm’s venture capital orientation typically suits high-growth technology companies rather than traditional middle-market acquisitions.
Sources
[S1] https://www.gv.com/about (as of 2025-01-15)
[S2] https://www.gv.com (as of 2025-01-15)
Frequently asked questions
Does GV buy AI Applications businesses?
Yes, GV maintains an active portfolio in AI applications, with publicly disclosed investments including Vercel, Synthesia, Tessl, Harvey, and Hebbia [S2]. The firm’s recent portfolio activity suggests continued interest in artificial intelligence-enabled businesses across both application and infrastructure layers.
What companies has GV acquired recently?
GV’s recent public activity consists primarily of exits rather than acquisitions. In 2025, the firm reported exits from Maze Therapeutics, Metsera, and Caraway Health, among others [S1]. In 2024, exits included Celsius Therapeutics, Cacheflow, and PayRange [S1].
Where is GV based and how big is the firm?
GV is headquartered in the San Francisco Bay Area with additional offices in New York, Cambridge, and London [S1]. The firm reports approximately $13 billion in assets under management as of January 2025 [S1].
Is GV still actively acquiring?
Based on twelve reported exit transactions in 2024 and 2025, GV appears to maintain an active portfolio management posture [S1]. However, the available public data reflects exit activity rather than new acquisitions during this period.
This profile is maintained by CT Acquisitions as an independent third-party reference. CT Acquisitions is not affiliated with, endorsed by, or a representative of the firm profiled. All facts sourced from publicly available materials as of the dates cited.